

Food and Drug Administration
Rockville MD 20857

NDA 88-627

Appn. 3/6/85

Lemmon Company
Attention: Stanley Scheindlin, D.Sc.
Post Office Box 630
Sellersville, PA 18960

Gentlemen:

Reference is made to your abbreviated new drug application dated December 1, 1983 submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Acetaminophen and Codeine Phosphate Tablets, 300 mg/15 mg.

Reference is also made to your communication dated February 7, 1985.

We have completed the review of this abbreviated new drug application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated new drug application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

This Administration should be advised of any change in the marketing status of this drug.

The requirement for adequate data to assure the biologic availability is being deferred at the present time. However, our action in approving this application is based upon an understanding that if this requirement is reinstated you will perform the appropriate procedures.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Also, please do not use Form FD-2253 for this submission.


For Subsequent Campaigns: We call your attention to Regulation 21 CFR 310.300(b)(3) which requires that all material for any subsequent advertising or promotional campaigns at the time of their initial use be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253. A copy of Form FD-2253 is enclosed for your convenience.



Page 2

The enclosures summarize the conditions relating to the approval of this application.

Sincerely yours,

A handwritten signature in cursive script that reads "Marvin Seife". The signature is written in black ink and is positioned above the typed name and title.

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics